[Selective IgA deficiency]

Area of Science:

• Immunology
• Clinical Medicine

Background:

• Selective IgA deficiency (SIgAD) is defined by low serum IgA (<0.07g/L) in individuals over 4 years old, with normal IgG, IgM, and vaccine responses.
• It is the most prevalent primary immunodeficiency in Europe, affecting approximately 1 in 600 individuals in France.
• A significant majority (75-90%) of patients with SIgAD remain asymptomatic.

Purpose of the Study:

• To define Selective IgA deficiency (SIgAD) based on European Society for Immunodeficiencies (ESID) criteria.
• To outline the clinical manifestations and management strategies for SIgAD.
• To emphasize the importance of an interdisciplinary approach for patient care.

Main Methods:

• Diagnostic criteria involve serum IgA levels below 0.07g/L, normal IgG and IgM, and adequate vaccine responses, excluding secondary causes.
• Clinical data and potential complications associated with SIgAD were reviewed.
• Management strategies were assessed based on patient's clinical status and comorbidities.

Main Results:

• Common complications include recurrent respiratory and gastrointestinal infections, autoimmune conditions, and allergic reactions.
• Anaphylaxis can occur if IgA-containing blood products are administered.
• Partial IgA deficiency, with IgA levels above 0.07g/L but below age-specific norms, is also recognized.

Conclusions:

• There is no specific cure for SIgAD; management is individualized.
• Asymptomatic patients require up-to-date vaccinations.
• Treatment may include prophylactic antibiotics for recurrent infections or immunoglobulin replacement therapy for those with concomitant IgG subclass deficiency.